Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
12
05
2021
revised:
12
08
2021
accepted:
19
08
2021
pubmed:
26
9
2021
medline:
15
12
2021
entrez:
25
9
2021
Statut:
ppublish
Résumé
Diabetes mellitus is a complex disease. We are increasingly gaining a better understanding of its mechanisms at the molecular level. From these new insights, better therapeutic approaches should emerge. Diabetes mellitus is a syndrome with many associated subphenotypes. These include mitochondrial disorders, lipodystrophies, and inflammatory disorders involving cytokines. Levels of sphingosine-1-phosphate, which has recently been shown to play a role in glucose homeostasis, are low in diabetics, whereas levels of ceramides are increased. Major phenotypes associated with diabetes mellitus are dyslipidemias, notably hypertriglyceridemia and low high-density lipoprotein cholesterol levels. Both diabetes and dyslipidemia are strongly associated with increased risk for atherosclerotic vascular disease.
Identifiants
pubmed: 34562838
pii: S1471-4892(21)00134-X
doi: 10.1016/j.coph.2021.08.013
pii:
doi:
Substances chimiques
Lipoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-27Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.